TL;DR
This project aims to utilise a genome-wide CRISPR-Cas9 knockout screen to identify novel senolytic drug targets whilst providing new mechanistic insights into how senescent cells function and survive.
Background information
Cellular senescence is a phenomenon in which damaged or stressed cells irreversibly exit the cell cycle and adopt a pro-inflammatory phenotype, disrupting tissue homeostasis and causing cytotoxic effects on neighbouring cells.
Senescent cells accumulate with age in humans and are associated with numerous diseases, including osteoarthritis, cardiovascular disease, cancer, and neurodegeneration. In animal models, the targeted removal of senescent cells has been shown to improve health and extend lifespan. Consequently, there is substantial therapeutic interest in developing senolytics - drugs that selectively eliminate senescent cells<sup>1</sup>.
As global populations continue to age and the incidence of age-related diseases rises, the need for effective interventions grows accordingly. As the removal of senescent cells has the potential to address a broad spectrum of age-associated conditions, the global market for senolytics is positioned to be a multibillion-dollar opportunity across multiple therapeutic areas.
Approach
Synthetic lethality is the biological phenomenon whereby inactivation of either gene A or B is tolerable, yet the loss of both is lethal<sup>2</sup>. Using this approach for target discovery has seen great success in the cancer field, for example the development of PARP inhibitors for treating BRCA-deficient